
229 Patients (pts) randomized
29 Italian centers (Jul 2015 – Oct 2017)
16 pts not clinically evaluable
213 pts clinically evaluable
36 pts without available baseline liquid biopsy (LB)
20 pts without evaluable baseline LB
157 pts with evaluable LB
26 pts with right-sided primary
1 pt with *BRAF* V600E mutation
5 pts with *HER2* amplification
5 pts with MSI
120 evaluable pts with left-ided, RAS/BRAF wt, HER2-neg, MSS mCRC
62 pts in ARM A
58 pts in ARM B